R L Heilman

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal
    Raymond L Heilman
    Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, USA
    Transplantation 93:47-53. 2012
  2. ncbi Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date
    Raymond L Heilman
    Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona 85054, USA
    Drugs 70:793-804. 2010
  3. ncbi Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients
    R L Heilman
    Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ
    Am J Transplant 10:563-70. 2010
  4. ncbi Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression
    Raymond L Heilman
    Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    Clin Transplant 22:309-15. 2008
  5. ncbi Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal
    Raymond L Heilman
    Department of Medicine, Mayo Clinic in Arizona, Phoenix, AZ 85054, USA
    Transplantation 92:767-73. 2011
  6. ncbi Steroid avoidance immunosuppression in low-risk kidney transplant recipients
    R L Heilman
    Division of Nephrology, Mayo Clinic Hospital, Kidney and Pancreas Program and Mayo Clinic College of Medicine, Phoenix, Arizona 85054, USA
    Transplant Proc 37:1785-8. 2005
  7. ncbi Outcomes after simultaneous pancreas and kidney transplantation and the discriminative ability of the C-peptide measurement pretransplant among type 1 and type 2 diabetes mellitus
    H A Chakkera
    Mayo Clinic, Scottsdale, Arizona, USA
    Transplant Proc 42:2650-2. 2010
  8. ncbi Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab
    R L Heilman
    Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Transplant Proc 38:1307-13. 2006
  9. ncbi Deceased donor kidney transplantation from donors with acute renal failure due to rhabdomyolysis
    K L Mekeel
    Division of Transplantation, Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, AZ, USA
    Am J Transplant 9:1666-70. 2009
  10. ncbi Diffuse parenchymal urine leak after kidney transplantation following degloving injury during donor nephrectomy
    K L Mekeel
    Department of Transplant Surgery, Mayo Clinic, Phoenix, AZ, USA
    Am J Transplant 7:2039-41. 2007

Collaborators

Detail Information

Publications17

  1. ncbi Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal
    Raymond L Heilman
    Department of Medicine, Mayo Clinic, Phoenix, AZ 85054, USA
    Transplantation 93:47-53. 2012
    ..Calcineurin-inhibitor therapy is a contributing factor to the origin of interstitial fibrosis and tubular atrophy (IFTA)...
  2. ncbi Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date
    Raymond L Heilman
    Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona 85054, USA
    Drugs 70:793-804. 2010
    ..Recent analysis of registry data shows that most transplant centres are using an induction agent followed by a combination of tacrolimus, MMF and corticosteroids in SPKT recipients...
  3. ncbi Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients
    R L Heilman
    Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ
    Am J Transplant 10:563-70. 2010
    ..In a multivariate analysis, patients in groups 2 or 3 had a higher risk of IF/TA score > 2 on the 1-year biopsy (OR 6.62, 95% CI 2.68-16.3). We conclude that SCI and SAR increase the risk of developing IF/TA in patient on RSW...
  4. ncbi Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression
    Raymond L Heilman
    Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ 85054, USA
    Clin Transplant 22:309-15. 2008
    ..Recent studies have documented good patient and graft outcomes and a low risk of acute rejection with steroid-avoidance immunosuppression in kidney-transplant recipients, but the risk of progressive graft fibrosis is not well studied...
  5. ncbi Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal
    Raymond L Heilman
    Department of Medicine, Mayo Clinic in Arizona, Phoenix, AZ 85054, USA
    Transplantation 92:767-73. 2011
    ..The use of calcineurin inhibitors is associated with chronic nephrotoxicity and lower glomerular filtration rate (GFR). As a result, one strategy of transplant immunosuppression is calcineurin inhibitor elimination...
  6. ncbi Steroid avoidance immunosuppression in low-risk kidney transplant recipients
    R L Heilman
    Division of Nephrology, Mayo Clinic Hospital, Kidney and Pancreas Program and Mayo Clinic College of Medicine, Phoenix, Arizona 85054, USA
    Transplant Proc 37:1785-8. 2005
    ..8% and 96.8%, respectively. SA with anti-thymocyte globulin induction in low-immunologic risk kidney transplant recipients is safe and is associated with a low risk of BPAR. The incidence of PTDM appears to be lower...
  7. ncbi Outcomes after simultaneous pancreas and kidney transplantation and the discriminative ability of the C-peptide measurement pretransplant among type 1 and type 2 diabetes mellitus
    H A Chakkera
    Mayo Clinic, Scottsdale, Arizona, USA
    Transplant Proc 42:2650-2. 2010
    ..However, because the kidney is the major site for C-peptide catabolism, C-peptide is unreliable to discriminate the type of diabetes in patients with kidney disease...
  8. ncbi Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab
    R L Heilman
    Division of Nephrology and Hypertension, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Transplant Proc 38:1307-13. 2006
    ..001). Median time to biopsy-proven acute rejection was 27 and 71 days, respectively. The low incidence of biopsy-proven acute rejection with steroid-avoidance immunosuppression may be further reduced with antithymocyte globulin...
  9. ncbi Deceased donor kidney transplantation from donors with acute renal failure due to rhabdomyolysis
    K L Mekeel
    Division of Transplantation, Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, AZ, USA
    Am J Transplant 9:1666-70. 2009
    ..3 (0.7-1.8). In conclusion, our experience suggests that rhabdomyolysis with acute renal failure should not be a contraindication for donation, although recipients may experience slow or delayed graft function...
  10. ncbi Diffuse parenchymal urine leak after kidney transplantation following degloving injury during donor nephrectomy
    K L Mekeel
    Department of Transplant Surgery, Mayo Clinic, Phoenix, AZ, USA
    Am J Transplant 7:2039-41. 2007
    ..The patient was successfully treated with tissue glue treatment to the kidney surface and peritoneal window...
  11. ncbi Impact of acute rejection on kidney allograft outcomes in recipients on rapid steroid withdrawal
    R L Heilman
    Department of Medicine, Mayo Clinic, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
    J Transplant 2011:583981. 2011
    ..06, 95% CI 3.39-24.2) and between the SR and control group (HR 4.22, 95% CI 1.30-13.7). Conclusion. Both SR and CR are associated with an inferior graft survival in recipients on RSW...
  12. ncbi Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation
    H A Chakkera
    Division of Transplantation Medicine, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85259, Arizona, USA
    Transplant Proc 41:4172-7. 2009
    ..Several genetic polymorphisms have been shown to be associated with T2DM. We hypothesized that transplant recipients who carry risk alleles for T2DM are "tipped over" to develop diabetes mellitus in the posttransplant milieu...
  13. ncbi Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation
    H A Chakkera
    Division of Nephrology, Mayo Clinic, Phoenix, Arizona 85054, USA
    Transplant Proc 45:137-41. 2013
    ..Native Americans required significantly lower tacrolimus doses than Caucasians to achieve similar tacrolimus trough levels, in part due to lower tacrolimus clearance from decreased drug metabolism and excretion...
  14. ncbi Successful transplantation of a split crossed fused ectopic kidney into a patient with end-stage renal disease
    Kristin L Mekeel
    Division of Transplant, Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Phoenix, AZ 85054, USA
    J Transplant 2010:383972. 2010
    ..The transplant was uncomplicated, and the graft had immediate function. The patient is now two years from transplant with excellent function...
  15. ncbi Kluyvera co-infection in two solid organ transplant recipients: an emerging pathogen or a colonizer bystander?
    R Cheruvattath
    Division of Transplantation Medicine, Mayo Clinic Hospital, Phoenix, AZ 85054, USA
    Transpl Infect Dis 9:83-6. 2007
    ..The isolation of Kluyvera as a pathogen in transplant patients emphasizes that this commensal organism may be virulent in this patient population...
  16. ncbi Coccidioidomycosis after renal transplantation in an endemic area
    C M Braddy
    Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA
    Am J Transplant 6:340-5. 2006
    ..Treatment for acute rejection and induction with antithymocyte globulin did not appear to increase the risk of subsequent coccidioidomycosis...
  17. ncbi Early detection of acute renal failure by serum cystatin C: a new opportunity for a hepatologist
    Marek J Mazur
    Transplant Medicine and Nephrology, Mayo Clinic Hospital, Phoenix, AZ, USA
    Liver Transpl 11:705-7. 2005